跳至主要内容
临床试验/NCT01438827
NCT01438827已完成2 期

Avanz Phleum Pratense Maintenance Dose

ALK-Abelló A/S1 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2011年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
450
试验地点
1
主要终点
Recording of symptomatic allergy medication use

研究概览

简要总结

The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass pollen induced allergic rhinoconjunctivitis with or without asthma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • A history of grass pollen allergy
  • Positive skin prick test to grass
  • Positive Immunoglobulin E test to grass

排除标准

  • Other allergies overlapping the grass pollen season
  • Severe Asthma (defined as a Forced expiratory volume in 1 second (FEV1) below 70 % after adequate treatment)

研究组 & 干预措施

Avanz Phleum pratense 15,000 SQ+

Active Comparator

干预措施: Avanz Phleum pratense (Drug)

Avanz Phleum pratense 4,000 SQ+

Active Comparator

干预措施: Avanz Phleum pratense (Drug)

Injection with no active grass component

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Recording of symptomatic allergy medication use

时间窗: Daily recordings during the grass pollen seasons 2012

Recording of rhinoconjunctivitis symptoms

时间窗: Daily recordings during the grass pollen season 2012

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验